Abstract
Systemic lupus erythematosus (SLE) is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in SLE patients affected by disease for more than 5 years is cardiovascular disease (CVD). Epidemiological observations suggest that, together with classical conventional risk factors, other mechanisms (non-conventional/disease-specific factors) promote accelerated atherosclerosis in inflammatory diseases like SLE. Traditional CVD risk factors included age, hypertension, diabetes mellitus, dyslipidemia, previous vascular event defined as previous history of cerebrovascular accidents or ischemic heart disease, menopause and smoking. The nontraditional factors presents in SLE are disease-specific like renal disease manifestation as Lupus nephritis (LN), presence of pro-inflammatory cytokines, some of inflammatory mediators, antiphospholipid antibodies, anti-oxLDL antibodies, corticosteroid uses and cumulative dose of glucocorticoids. We will review traditional and non-traditional risk factors associated with CVD in SLE patients.
Keywords: Nontraditional risk factors, cardiovascular disease, systemic lupus erythematosus
Current Cardiology Reviews
Title:Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Volume: 9 Issue: 1
Author(s): Nailu Angelica Sinicato, Priscila Aparecida da Silva Cardoso and Simone Appenzeller
Affiliation:
Keywords: Nontraditional risk factors, cardiovascular disease, systemic lupus erythematosus
Abstract: Systemic lupus erythematosus (SLE) is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in SLE patients affected by disease for more than 5 years is cardiovascular disease (CVD). Epidemiological observations suggest that, together with classical conventional risk factors, other mechanisms (non-conventional/disease-specific factors) promote accelerated atherosclerosis in inflammatory diseases like SLE. Traditional CVD risk factors included age, hypertension, diabetes mellitus, dyslipidemia, previous vascular event defined as previous history of cerebrovascular accidents or ischemic heart disease, menopause and smoking. The nontraditional factors presents in SLE are disease-specific like renal disease manifestation as Lupus nephritis (LN), presence of pro-inflammatory cytokines, some of inflammatory mediators, antiphospholipid antibodies, anti-oxLDL antibodies, corticosteroid uses and cumulative dose of glucocorticoids. We will review traditional and non-traditional risk factors associated with CVD in SLE patients.
Export Options
About this article
Cite this article as:
Angelica Sinicato Nailu, Aparecida da Silva Cardoso Priscila and Appenzeller Simone, Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus, Current Cardiology Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573403X11309010003
DOI https://dx.doi.org/10.2174/1573403X11309010003 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
Call for Papers in Thematic Issues
Advances in Managing Cardiogenic Shock and the Value of Percutaneous Mechanical Circulatory Support.
Despite the advances in cardiology, the outcomes of patients with cardiogenic shock remain poor. There is an increasing interest and use of mechanical circulatory support for patients with cardiogenic shock. Additionally, the complexity of coronary interventions has increased during the last decade with the potential of treating more high-risk patients ...read more
Chronic Disease Self-Management for Heart Failure – A Mini review into Performance Gaps
Chronic disease self-management (CDSM)is a vital component of chronic disease management. There remain several important deficits in this concept. Its benefit are clear, many chronic diseases such as hypertension, diabetes, asthma, rheumatology syndromes have shown benefit in quality of life and quantitative measures of outcomes. Yet, in congestive heart failure ...read more
The era of cardiac medication and implantable devices therapy in heart failure treatment continues
The heart failure (HF) remains a serious public health problem and affects 64 million people worldwide. Although advances in medical therapy and device assistance have significantly improved HF outcomes, the implications of HF are still dramatic. In recent years, innovative developments have been made in HF treatment management, based on ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges
Current Pharmaceutical Design Novel Agents to Manage Dyslipidemias and Impact Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design The Fluctuations of Melatonin and Copeptin Levels in Blood Serum During Surgical Stress Regarding the Pediatric Population
Current Pediatric Reviews Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature
Recent Advances in Inflammation & Allergy Drug Discovery Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery Blood Coagulation and the Risk of Atherothrombosis
Current Genomics The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Current Pharmaceutical Design Sea, Carbohydrates and Clotting: A Triad on the Road of Drug Discovery
Mini-Reviews in Medicinal Chemistry Immune Response to Native Lipoproteins Induces Visceral Obesity and Aortic Wall Injury in Rats: The Role of Testosterone
Endocrine, Metabolic & Immune Disorders - Drug Targets Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition